Actively Recruiting
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
Led by National Taiwan University Hospital · Updated on 2024-06-18
900
Participants Needed
1
Research Sites
356 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
CONDITIONS
Official Title
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects suspected or confirmed diagnosis of lung cancer.
- Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography.
- Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
- Subjects age over 20.
You will not qualify if you...
- Pregnancy.
- Subjects with HIV infection.
- Unable to or unwilling to give informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100225
Actively Recruiting
Research Team
H
Hsing-Chen Tsai, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here